Psoriasis Treatment and Healthcare Resource Utilisation
By Melike Belenli Gümüş
August 14, 2024
Introduction
Psoriasis, a chronic inflammatory skin condition affecting working-age individuals, primarily manifests as psoriasis vulgaris, constituting over 80% of cases. Psoriasis treatment and healthcare resource utilisation (HCRU) are critical topics in dermatology. Linked to various comorbidities like psoriatic arthritis and cardiovascular diseases, psoriasis imposes a substantial healthcare burden, particularly in Europe where it affects 1-5% of the population. Biologics targeting immune pathways have significantly advanced treatment, yet real-world data on HCRU patterns remain scarce.
Understanding Psoriasis Burden and Comorbidities
A retrospective study from Finland provided a comprehensive analysis of the real-world impact of biologic treatments on HCRU in psoriasis patients. In Finland, psoriasis treatment aligns with Current Care Guidelines, reserving biologics for severe cases unresponsive to initial therapies. The study analysed data from Finnish national health registers, focusing on patients who initiated biologic or conventional treatments between January 2013 and December 2017. The biologics included in the study were adalimumab, brodalumab, etanercept, secukinumab, ixekizumab, certolizumab pegol, and ustekinumab, as they are reimbursable for psoriasis treatment in Finland. Conventional treatments included cyclosporine, methotrexate, and acitretin. Biologic initiators, predominantly male, exhibited higher rates of immune-mediated comorbidities compared to conventional starters.
Key Findings
Reduction in Dermatology Visits
One of the most significant findings was the reduction in dermatology visits among biologic starters. The mean annual number of dermatologist contacts decreased from 5.4 to 2.3 per person after initiating biologic treatment. This reduction highlights the effectiveness of biologics in managing psoriasis, leading to fewer healthcare visits.
Impact on Primary and Secondary Care
While dermatology visits decreased, the mean annual number of primary care and other secondary care contacts slightly increased after starting biologics. Primary care contacts rose from 8.7 to 9.1 per person, and secondary care contacts increased from 3.9 to 4.1. These findings suggest that while biologics reduce the need for specialised dermatology care, they may lead to increased interactions with less costly healthcare providers.
Figure 1: Contact rates per category before and after the initiation of the first and the second (A) biologic, and (B) conventional.
Treatment Switching
Switching treatments, common in both groups, influenced HCRU differently. Approximately 32.3% of biologic starters and 19% of conventional starters switched treatments at least once during the observation period. Biologic switchers experienced milder peaks in dermatologist visits, indicating smoother transitions. Conversely, conventional switchers exhibited heightened dermatologist contacts pre-switch, suggesting unmet treatment needs. Notably, non-switching biologic users demonstrated lower overall HCRU compared to switchers, implying treatment continuity’s positive impact.
Figure 2: Contact rates by category (primary care, dermatology, secondary care excluding dermatology) before and after the initiation of the first (A) biologic / (B) conventional in different subgroups. Subgroups were defined as follows, patients who: persisted on the first treatment ≥12 months; switched a biologic or conventional once during the 2-year period after the initiation of the first treatment; switched a biologic or conventional more than once during the 2-year period after the initiation of the first treatment; continued the first treatment <12 months from the initiation and did not start a new medication within the medication group.
Limitations and Considerations
The study had several limitations, including a lack of detailed clinical information and the exclusion of private and occupational healthcare data. Besides, the analysis did not include drugs administered in hospitals, such as intravenous infliximab. Despite these limitations, the study provides valuable insights into the real-world impact of biologics on HCRU in psoriasis patients.
Conclusion
This study demonstrates the benefits of biologic treatments in reducing dermatology visits and highlights the importance of considering patient needs and preferences in psoriasis management. As the number of treatment options continues to grow, understanding the real-world impact of these treatments becomes increasingly important. The findings support the use of biologics to improve patient outcomes and reduce the burden on healthcare systems.
💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.
💉 Ready to protect our future generations from cervical cancer?
The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.
Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.
🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?
The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.
#SyenzaNews #pharmaceuticals #healthcarepolicy
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
